According to Zhitong Finance App News, First Pharmaceutical Holdings (688197.SH) issued an announcement. According to the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (“National Medical Insurance Drug Catalogue”) officially announced by the National Health Security Administration and the Ministry of Human Resources and Social Security, the company's innovative product, Cantetinib granules (trade name: Chuangze®) passed the national health insurance negotiations and was included in the new national medical insurance drug catalogue for the first time. The medical insurance coverage of this drug is limited to ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients not treated with anaplastic lymphoma kinase (ALK) inhibitors.

Zhitongcaijing · 1d ago
According to Zhitong Finance App News, First Pharmaceutical Holdings (688197.SH) issued an announcement. According to the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (“National Medical Insurance Drug Catalogue”) officially announced by the National Health Security Administration and the Ministry of Human Resources and Social Security, the company's innovative product, Cantetinib granules (trade name: Chuangze®) passed the national health insurance negotiations and was included in the new national medical insurance drug catalogue for the first time. The medical insurance coverage of this drug is limited to ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients not treated with anaplastic lymphoma kinase (ALK) inhibitors.